| Popis: |
Additional file 1: Table S1. Mean diameter size and tensile modulus of PCL/VMT composite scaffolds. Table S2. Released ion concentration of Si and Mg in cell culture medium after incubation for 2 days in the presence of PCL/5%VMT scaffolds. Table S3. Quantitative Real-time PCR primer sequences. Table S4. Antibodies used for Western blot or Immunofluorescence. Figure S1. SEM images of the PCL, PCL/2.5%VMT, PCL/5%VMT, and PCL/10%VMT fibrous composite scaffolds. Figure S2. XRD patterns of PCL, PCL/VMT, and VMT NSs. Figure S3. Size distributions of the PCL, PCL/2.5%VMT, PCL/5%VMT, and PCL/10%VMT fibrous composite scaffolds.Figure S4. (A) Stress-strain curves and (B) tensile modulus ofthe PCL, PCL/2.5%VMT, PCL/5% VMT, and PCL/10%VMT composite scaffolds. Figure S5.(A) SEM images and (B) corresponding size distributions of the PCL, PCL/2.5%VMT, PCL/5%VMT, and PCL/10%VMT composite scaffolds immersed in PBS solutions for 14 days. Figure S6. In vitro hemolysis assay of the PCL, PCL/2.5%VMT, PCL/5%VMT, and PCL/10%VMT composite scaffolds. (A) Photographs and (B) absorbance of supernatants of RBCs exposed to different samples. Figure S7. Effects of PCL/VMT composite scaffolds on NO production in MAECs. (A) Representative fluorescent images of intracellular NO production detected by using DAF-FM probe after incubation for 72 h. (B) The amount of NO released into cell medium from MAECs cultured on the different composite scaffolds after incubation for 72 h using Griess reaction assay kits. Figure S8. Effects of PCL/VMT composite scaffolds on the expression of inflammatory factors in RAW 264.7. Relative mRNA expression of iNOS and Arg in the RAW 264.7 treated with PCL, PCL/2.5%VMT, PCL/5%VMT, PCL/10%VMT without (A) and with (B) LPS. |
